This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

Brighter Management

Management Kriterienprüfungen 1/4

Wichtige Informationen

Erik Lissner

Geschäftsführender

kr824.0k

Gesamtvergütung

Prozentsatz des Geschäftsführergehalts	n/a
Amtszeit als Geschäftsführer	1.3yrs
Eigentum des Geschäftsführers	0.05%
Durchschnittliche Amtszeit des Managements	1.8yrs
Durchschnittliche Amtszeit der Vorstandsmitglieder	1.8yrs

Jüngste Management Updates

Recent updates

Geschäftsführer

Erik Lissner (55 yo)

1.3yrs

Amtszeit

kr824,000

Vergütung

Mr. Erik Lissner serves as Chief Executive Officer of Brighter AB (publ) since June 30, 2022 and served as its Acting Chief Executive Officer at since January 2022 until June 30, 2022. He had been an Inter...

Führungsteam

Name	Position	Amtszeit	Vergütung	Eigentümerschaft
Erik Lissner	Chief Executive Officer	1.3yrs	kr824.00k	0.049% SEK 7.2k
Malin Hollander	Acting Chief Financial Officer	less than a year	keine Daten	keine Daten
Jonas Johansson	Head of Operations	1.8yrs	keine Daten	keine Daten
Magnus Schnürer	Chief Technology Officer	no data	keine Daten	keine Daten
Bruce McGinn	Head of Legal	no data	keine Daten	keine Daten
Marie-Louise Kanon	Head of Communication & Brand	1.8yrs	keine Daten	0.011% SEK 1.6k
Johan Moller	Head of Sales & Marketing	1.8yrs	keine Daten	keine Daten
Maja Roslund	Head of People & Culture	3.8yrs	keine Daten	0.0092% SEK 1.4k
Kjell Rundqvist	Head of Logistics and Customer Service	no data	keine Daten	keine Daten
Yulianto Blom	Head of Production	no data	keine Daten	0.00047% SEK 69.4
Dragan Zdravkovic	Head of Medical Affairs	2.8yrs	keine Daten	0.018% SEK 2.6k

1.8yrs

Durchschnittliche Betriebszugehörigkeit

Erfahrenes Management: 2HJ's management team is not considered experienced ( 1.8 years average tenure), which suggests a new team.

Vorstandsmitglieder

Name	Position	Amtszeit	Vergütung	Eigentümerschaft
Clas Lindbergson	Independent Director	1.8yrs	kr100.00k	0.024% SEK 3.6k
Asa Nordgren	Independent Director	2.8yrs	kr220.00k	0.024% SEK 3.6k
Christer Tragardh	Chairman of the Board	1.8yrs	kr1.54m	0.36% SEK 53.0k
Karin O'Connor	Independent Director	1.8yrs	kr100.00k	0.024% SEK 3.6k
Johnny Ludvigsson	Director	less than a year	keine Daten	keine Daten

1.8yrs

Durchschnittliche Betriebszugehörigkeit

Erfahrener Vorstand: 2HJ's board of directors are not considered experienced ( 1.8 years average tenure), which suggests a new board.

This company listing is no longer active

Brighter Management

Management Kriterienprüfungen 1/4

Wichtige Informationen

Jüngste Management Updates

Brighter AB (publ) Announces Executive Changes

High number of new and inexperienced directors

High number of new and inexperienced directors

Brighter's Interim CEO Erik Lissner Takes Permanent Role as the Company CEO

Brighter AB (Publ) Announces Appointment of Johnny Ludvigsson as Board Member

High number of new and inexperienced directors

Recent updates

Nasdaq Stockholm AB Decides to Delist the Shares and Equity Rights of Brighter AB

Nasdaq Stockholm imposes a fine on Brighter AB (publ)

Brighter AB (Publ) Applies for Corporate Restructuring in Bid for Longer-Term Financing

Brighter AB (publ) Announces Executive Changes

Brighter AB (publ) to Report Fiscal Year 2022 Results on Apr 13, 2023

Second quarter 2022 earnings released: kr0.05 loss per share (vs kr0.21 loss in 2Q 2021)

Brighter AB (Publ.) Announces its Actiste® Receives Telecommunication Type Approval in the United Arab Emirates

High number of new and inexperienced directors

Brighter AB (publ) Receives Final Approvals for Pilot Research with Insulin-Treated Diabetes Patients in the UAE

High number of new and inexperienced directors

Brighter's Interim CEO Erik Lissner Takes Permanent Role as the Company CEO

Brighter AB Announces Actiste®, for the First Time, Is Prescribed to A Patient Living with Diabetes in Qatar

700Brighter AB Announces Actiste, for the First Time, Is Prescribed to A Patient Living with Diabetes in Qatar

Brighter AB (Publ) Announces Appointment of Johnny Ludvigsson as Board Member

Brighter AB (publ) Announces First Patient Recruited for the Actiste Study in the United Kingdom

First quarter 2022 earnings released: kr0.07 loss per share (vs kr0.20 loss in 1Q 2021)

High number of new and inexperienced directors

Full year 2021 earnings released: kr0.60 loss per share (vs kr1.08 loss in FY 2020)

Brighter AB (Publ) Announces Launch and Commercial Availability of its Actiste® Service, Aiming to Improve the Quality of Life for People Living with Diabetes in Qatar

Full year 2021 earnings: EPS in line with analyst expectations despite revenue beat

Brighter AB (publ) to Report Fiscal Year 2021 Results on Apr 13, 2022

Brighter AB (publ) to Report Q3, 2022 Results on Nov 09, 2022

Brighter AB (publ), Annual General Meeting, May 05, 2022

Brighter AB (publ) has completed a Composite Units Offering in the amount of SEK 117.093404 million.

Brighter AB (publ) announces positive results for Actiste®

A shareholder of Blodtrycksdoktorn AB entered into an agreement to acquire an unknown stake in Blodtrycksdoktorn AB from Brighter AB (publ) (OM:BRIG) for SEK 5 million.

Beijing AddLife AB (publ) (OM:ALIF B) acquired Camanio AB from Brighter AB (publ) (OM:BRIG) for SEK 65 million.

Third quarter 2021 earnings released: kr0.20 loss per share (vs kr0.18 loss in 3Q 2020)

Brighter's Actiste Receives Final Outstanding Approval in Qatar

Interim Chief Financial Officer Julie Silber has left the company

Second quarter 2021 earnings released: kr0.20 loss per share (vs kr0.27 loss in 2Q 2020)

Brighter's Actiste Receives Telecommunication Approval in Qatar

Brighter's Actiste Mini Receives Telecommunication Approval in Qatar

Compatibility with New Insulins Opens Up New Market Opportunities for Brighter's Actiste

Brighter AB (Publ) Launches Innovative Pilot Project with Tomelilla Municipality

Brighter AB (Publ) Provides Revenue Guidance for the Year 2021

Brighter AB (Publ) Makes Progress with the User Experience Test of the Diabetes Management Solution Actiste

First quarter 2021 earnings released: kr0.20 loss per share (vs kr0.19 loss in 1Q 2020)

Brighter AB (Publ) Announces the Patent to Safely Combine MDD and IVDD Functionality into One Unit

Full year 2020 earnings released: kr1.04 loss per share (vs kr1.06 loss in FY 2019)

Brighter AB (publ) to Report Q4, 2021 Results on Feb 20, 2022

Brighter Signs 5-Year Distribution Agreement for Actiste in Qatar

Brighter AB (publ) Announces CEO Changes

Brighter AB (publ) Announces Diabetes Management Devices Actiste and Actiste Mini Receives Market Approval in Thailand

Brighter AB (publ) Announces Clarification of Information Regarding Agreements for Nigeria and Ghana

Brighter AB (publ) Signs 5-Year Agreement with Wssonlines Nigeria Ltd and Receives Initial Order for Actiste® Worth Eur 2.3 Million in Nigeria

Brighter AB (publ)'s Actiste® Mini Receives Market Approval in the Kingdom of Saudi Arabia

Brighter AB (Publ) Announces Nomination Committee for the AGM 2021

New 90-day high: €0.31

Brighter AB (publ) Announces Executive Changes

Brighter's Pioneering Diabetes Management Solution Actiste® Receives Market Approval in the United Arab Emirates

Third quarter 2020 earnings released: kr0.16 loss per share

Brighter AB (Publ) Announces Actiste Device and Its Associated Digital Platform Received Market Approval from the Saudi Food and Drug Authority

Founder & Executive Director recently sold €143.8k worth of stock

First half earnings released

First half earnings released

Brighter AB (publ) to Report Q4, 2020 Results on Feb 12, 2021

New 90-day low - €0.30

New 90-day low - €0.30

Geschäftsführer

Amtszeit

Vergütung

Führungsteam

Durchschnittliche Betriebszugehörigkeit

Vorstandsmitglieder

Durchschnittliche Betriebszugehörigkeit